Investor
Relations
Recordati has been at the forefront of life-enhancing and life-changing medicines for the last 100 years, and has been listed on Italian stock exchange since 1984.
Underpinned by a history of strong financial delivery, we will continue to grow from within, capture opportunities within our own pipeline, and identify opportunities to bring in new treatments through acquisitions across all our businesses.
Investor
Relations
Recordati has been at the forefront of life-enhancing and life-changing medicines for the last 100 years, and has been listed on Italian stock exchange since 1984.
Underpinned by a history of strong financial delivery, we will continue to grow from within, capture opportunities within our own pipeline, and identify opportunities to bring in new treatments through acquisitions across all our businesses.
Conference call for the first quarter 2026 results, May 13th 14:00 CEST
Upcoming Events
No upcoming events found.
Date:
July 28, 2026
-
July 28, 2026
Board of Directors’ meeting to approve the 2026 half-yearly report.
Date:
July 29, 2026
-
July 29, 2026
At 2.00 pm (CEST): conference call on the results for the first half of 2026.
Date:
November 10, 2026
-
November 10, 2026
Board of Directors’ meeting to approve the 2026 first nine months’ results, as additional voluntary financial reporting.
Revenue trend 2021 - 2025 (million Euro)
Revenue by business unit 2021 - 2025 (million Euro)
Total Revenue split by Therapeutica area - FY 2025
(SPC 58.7%, Rare Disease 41.3%)
Note: Total OTC of € 334.9 million in FY 2024 and € 331.3 million in FY 2023
Pharmaceutical revenue (excluding Chemicals) split by Geographic - FY 2025
Key P&L Data
|
(million Euro)
|
FY 2025
|
|
FY 2024
|
|
FY 2023
|
|
FY 2022
|
|
FY 2021
|
|---|---|---|---|---|---|---|---|---|---|
|
Revenue
|
2,618.4
|
|
2,341.6
|
|
2,082.3
|
|
1,853.3
|
|
1,580.1
|
|
Gross Profit
as % of revenue |
1,787.7
68.3 |
|
1,600.3
68.3 |
|
1,422.6
68.3 |
|
1,286.6
69.4 |
|
1,152.3
72.9 |
|
Adjusted Gross Profit (1)
as % of revenue |
1,854.4
70.8 |
|
1,637.8
69.9 |
|
1,481.6
71.1 |
|
1,336.4
72.1 |
|
1,152.3
72.9 |
|
Operating Income (EBIT)
as % of revenue |
670.8
25.6 |
|
638.9
27.3 |
|
558.0
26.8 |
|
437.3
23.6 |
|
490.2
31.0 |
|
Adjusted Operating Income (Adj. EBIT) (2)
as % of revenue |
774.9
29.6 |
|
684.4
29.2 |
|
626.6
30.1 |
|
536.1
28.9 |
|
504.6
31.9 |
|
Net Income
as % of revenue |
443.6
16.9 |
|
416.5
17.8 |
|
389.2
18.7 |
|
312.3
16.9 |
|
386.0
24.4 |
|
Adjusted Net Income (3)
as % of revenue |
651.1
24.9 |
|
568.9
24.3 |
|
524.6
25.2 |
|
473.3
25.5 |
|
424.6
26.9 |
|
EBITDA (4)
as % of revenue |
991.1
37.8 |
|
865.8
37.0 |
|
769.6
37.0 |
|
672.8
36.3 |
|
602.3
38.1 |
1) Adjusted gross profit: Gross profit adjusted by the impact of non-cash charges arising from the allocation of the purchase price of EUSA Pharma and Enjaymo® to the gross margin of acquired inventory according to IFRS 3
2) Adjusted Operating Income: Net income before income taxes, financial income and expenses and non-recurring items, non-cash charges arising from the allocation of the purchase price of EUSA Pharma and Enjaymo® to the gross margin of acquired inventory according to IFRS 3.
3) Adjusted Net Income: Net income excluding the amortization and write-downs of intangible assets (except software) and goodwill, non-recurring items, non-cash charges arising from the allocation of the purchase price of EUSA Pharma and Enjaymo® to the gross margin of acquired inventory pursuant to IFRS 3, and monetary net gains/losses from hyperinflation (IAS 29), net of tax effects.
4) EBITDA: Net income before income taxes, financial income and expenses, depreciation, amortization and write-downs of property, plant and equipment, intangible assets and goodwill, non-recurring items and non-cash charges arising from the allocation of the purchase price of EUSA Pharma and Enjaymo® to the gross margin of acquired inventory according to IFRS 3
Balance Sheet at December 2025 (million Euro)
Net Debt - FY 2023 - 2025 (million Euro)
Net Debt / EBITDA1 - FY 2023 - 2025 (million Euro)
1) EBITDA: Net income before income taxes, financial income and expenses, depreciation, amortization and write-downs of property, plant and equipment, intangible assets and goodwill, non-recurring items and non-cash charges arising from the allocation of the purchase price of EUSA Pharma and Enjaymo® to the gross margin of acquired inventory according to IFRS 3
*Pro-forma calculated by adding Enjaymo’s® estimated contribution for the first eleven months of fiscal year 2024 (when it still was propriety of Sanofi) to EBITDA
Free Cash Flow1 - FY 2023 - 2025 (million Euro)
1) Operating cash flow excluding financing items, milestones, dividends, purchases of treasury shares net of proceeds from exercise of stock options
Adjusted Net Income Per Share (Euro)
Dividend per share (Euro)
Note on Dividend per Share 2025: Proposed by the Board of Directors
Net Income per share (Euro)
Presentations & Reports
Latest and previous presentations and reports including company presentations and financial results, annual & interim reports and archived materials…
Press Releases
Overview of our key milestones as a company and latest news and announcements